SyntheticGestalt
  • Top
  • Technology
  • Services
  • Culture
  • Company
  • Careers
  • Contact
  • News
  • Twitter
  • Facebook
  • Linkedin
  • Tokyo Office

    11F H1O Hamamatsucho, 1-2-14 Shibadaimon, Minato City, Tokyo, 105-0012

Contact
Privacy Policy

© SyntheticGestalt KK

Previous
Next

How KOYA and ZAO Fit Into Structure-Based Drug Discovery

2026-08-11
sg-corporate-logo-stacked-transparent.png

How KOYA and ZAO Fit Into Structure-Based Drug Discovery

Structure-based drug discovery starts with a shape: the three-dimensional geometry of a target — a binding pocket, an active site, an interface — that tells you what a molecule needs to look like to engage it. Getting from that shape to a validated lead candidate means moving between two questions, over and over, for every round of a program: what should we design next? and how good is what we just designed?

In practice those two questions tend to live in different tools, different file formats, and sometimes different teams — which is exactly where iteration cycles slow down. This is the gap KOYA and ZAO are built to close.

KOYA: design against the target structure

KOYA is SG's design tool. It works directly from a target's structural information to propose and refine candidate molecules — keeping each design decision anchored to the binding-site geometry that structure-based discovery depends on, rather than treating structure as a reference to check against after the fact.

ZAO: profile candidates before they move forward

ZAO is SG's profiling tool. It evaluates designed candidates computationally against the target structure, giving a program team a structural read on a candidate before it advances to the next stage of a pipeline.

Why the pairing matters

Used together, KOYA and ZAO keep design and evaluation in the same structural frame of reference at each step of a program, instead of treating "make a molecule" and "judge a molecule" as disconnected stages that only reconcile at a review meeting. Both are generally available today.

SG is also exploring a prioritization capability, HAKUBA, for early interest — this is pre-commercial, with an anticipated availability around 2027 Q4, and is not yet a product we can speak to in terms of completed capability. We'll have more to share on that as it develops.

Where this fits for research teams

If your team is evaluating AI-assisted tools for structure-based design and wants a technical conversation about how KOYA and ZAO fit into an existing pipeline, [contact SG] — happy to walk through specifics.

Previous
Next